FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1593-1595 October 14, 2004 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The introduction of drug-eluting coronary stents in the United States has rapidly and profoundly affected the field of interventional cardiology. Met with widespread anticipation by the clinical community, drug-eluting stents are now used in a majority of intracoronary stenting procedures, justifying their characterization as a "transforming technology." However, both such stents that are currently approved by the Food and Drug Administration (FDA), the Cordis Cypher sirolimus-eluting stent and the Boston Scientific Taxus Express² paclitaxel-eluting stent, have also been associated with highly publicized adverse events after they were approved for marketing, leading some to question their safety. As a by-product of . . . [Full Text of this Article]

Source Information

From the Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Md.

This article has been cited by other articles:

• Krucoff, M. W., Boam, A., Schultz, D. G. (2007). Drug-Eluting Stents "Deliver Heartburn": How Do We Spell Relief Going Forward?. Circulation 115: 2990-2994 [Full Text]  
• Farb, A., Boam, A. B. (2007). Stent Thrombosis Redux -- The FDA Perspective. NEJM 356: 984-987 [Full Text]  
• Nordmann, A. J., Briel, M., Bucher, H. C. (2006). Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27: 2784-2814 [Abstract] [Full Text]  
• Elezi, S., Dibra, A., Folkerts, U., Mehilli, J., Heigl, S., Schomig, A., Kastrati, A. (2006). Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease. J Am Coll Cardiol 48: 262-267 [Abstract] [Full Text]  
• Maisel, W. H., Moynahan, M., Zuckerman, B. D., Gross, T. P., Tovar, O. H., Tillman, D.-B., Schultz, D. B. (2006). Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports.. JAMA 295: 1901-1906 [Abstract] [Full Text]  
• Mehilli, J., Dibra, A., Kastrati, A., Pache, J., Dirschinger, J., Schomig, A., for the Intracoronary Drug-Eluting Stenting to Abr, (2006). Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27: 260-266 [Abstract] [Full Text]  
• Valgimigli, M., Percoco, G., Malagutti, P., Campo, G., Ferrari, F., Barbieri, D., Cicchitelli, G., McFadden, E. P., Merlini, F., Ansani, L., Guardigli, G., Bettini, A., Parrinello, G., Boersma, E., Ferrari, R., for the STRATEGY Investigators, (2005). Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial. JAMA 293: 2109-2117 [Abstract] [Full Text]  
• Cothren, C. C., Moore, E. E., Ray, C. E. Jr, Ciesla, D. J., Johnson, J. L., Moore, J. B., Burch, J. M. (2005). Carotid Artery Stents for Blunt Cerebrovascular Injury: Risks Exceed Benefits. Arch Surg 140: 480-486 [Abstract] [Full Text]  
• Goldstein, L. B., Amarenco, P. (2005). Prevention and Health Services Delivery. Stroke 36: 222-224 [Full Text]